Despite increasingly aggressive rhetoric from the agencies, 2022 was largely characterized as “business as usual” in the antitrust world. In contrast, 2023 featured a significant step.
The FTC announced yesterday that it would seek to block Sanofi’s proposed exclusive license agreement with Maze Therapeutics, having concluded that the transaction would “eliminate a.